Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background.

J Lipid Res · 2026 · PMC13122311 · PMID 41887531

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

showed a trendP = 0.063so close (0.05 < p ≤ 0.1)

Hepatic cholesteryl esters, on the other hand, were significantly reduced in the combination treatment group compared to untreated control mice (−22%) and showed a trend towards a significant reduction compared to mice treated with ezetimibe alone (−13%, P = 0.063) ( Fig. 3 D).

also in 53,322 other papers

borderline significantP = 0.065so close (0.05 < p ≤ 0.1)

Plaque stability index was calculated by dividing stabilizing factors (collagen + SMC content) by destabilizing factors (macrophage + necrotic core content) and showed a borderline significant increase in obicetrapib-treated mice (+74%, P = 0.065) that was not observed in ezetimibe-treated mice ( Fig. 4 H).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.